Genetically modified non-human animal with human or chimeric TIGIT

27-12-2022 дата публикации

Номер:

US0011534502B2

Автор: Yuelei Shen, YANG BAI, RUI HUANG, Yanan Guo, Xiaofei Zhou, Meiling Zhang

Принадлежит: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Контакты:

Номер заявки: 42-94-1632

Дата заявки: 30-08-2017

CPC - классификация

A A0 A01 A01K A01K2 A01K22 A01K220 A01K2207 A01K2207/A01K2207/1 A01K2207/12 A01K2207/15 A01K221 A01K2217 A01K2217/A01K2217/0 A01K2217/07 A01K2217/072 A01K2217/075 A01K222 A01K2227 A01K2227/A01K2227/1 A01K2227/10 A01K2227/105 A01K226 A01K2267 A01K2267/A01K2267/0 A01K2267/03 A01K2267/033 A01K2267/0331 A01K6 A01K67 A01K67/A01K67/0 A01K67/02 A01K67/027 A01K67/0276 A01K67/0278 A6 A61 A61K A61K4 A61K49 A61K49/A61K49/0 A61K49/00 A61K49/000 A61K49/0008 C C0 C07 C07K C07K1 C07K14 C07K14/C07K14/7 C07K14/70 C07K14/705 C07K14/7050 C07K14/70503 C07K2 C07K23 C07K231 C07K2319 C07K2319/C07K2319/0 C07K2319/00 C07K2319/03 C1 C12 C12N C12N1 C12N15 C12N15/C12N15/1 C12N15/11 C12N15/113 C12N15/8 C12N15/85 C12N15/850 C12N15/8509 C12N15/9 C12N15/90 C12N15/907 C12N2 C12N20 C12N201 C12N2015 C12N2015/C12N2015/8 C12N2015/85 C12N2015/857 C12N2015/8572 C12N23 C12N231 C12N2310 C12N2310/C12N2310/1 C12N2310/10 C12N25 C12N251 C12N2517 C12N2517/C12N2517/0 C12N2517/02 C12N28 C12N280 C12N2800 C12N2800/C12N2800/1 C12N2800/10 C12N2800/107

IPC - классификация

A A0 A01 A01K A01K6 A01K67 A01K67/A01K67/0 A01K67/02 A01K67/027 A6 A61 A61K A61K4 A61K49 A61K49/A61K49/0 A61K49/00 A61P A61P3 A61P35 A61P35/A61P35/0 A61P35/00 C C0 C07 C07K C07K1 C07K14 C07K14/C07K14/7 C07K14/70 C07K14/705 C1 C12 C12N C12N1 C12N15 C12N15/C12N15/1 C12N15/11 C12N15/113 C12N15/8 C12N15/85 C12N15/9 C12N15/90

Цитирование НПИ

Anderson et al., “Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized fuctions in immune regulation,” Immunity, 2016, 44(5):989-1004.
Auerbach et al., “Establishment and Chimera Analysis of 129/SvEv- and C57BL/6-Derived Mouse Embryonic Stem Cell Lines” BioTechniques, 2000, 29:1024-1032.
Chan et al., “Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer,” Current Opinion in Immunology, 2012, 24:246-251.
Chen et al., “T-cell immunoreceptor with Ig and ITIM domains precursor [Mus musculus, Accession No. NP_001139797.1” NCBI GenBank, 2016, 3 pages.
Extended European Search Report in EP Appln. No. 17845422, dated Feb. 5, 2020, 9 pages.
Festing et al., “Revised nomenclature for strain 129 mice,” Mammalian Genome, 1999, 10:836.
Gama Sosa et al., Animal transgenesis: an overview,: Brain Struct Funct, 2010, 214:91-109.
GenBank Accession No. EU675310.1, “Homo sapiens T cell immunoreceptor with Ig and ITIM domains (TIGIT) mRNA, complete cds,” GenBank, Apr. 23, 2008, 2 pages.
GenBank Accession No. EU675311.1, “Mus musculus T cell immunoreceptor with Ig and ITIM domains (Tigit) mRNA, complete cds,” GenBank, Apr. 23, 2008, 2 pages.
Hauschild et al., “Efficient generation of biallelic knockout in pigs using zinc-finger nucleases,” PNAS, 2011, 108 (29):12013-12017.
Ito et al., “NOD/SCID ycnull mouse: an excellent recipient mouse model for engraftment of human cells,” Blood, 2002, 100(9):3175-3182.
Johnston et al., “The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function,” Cancer cell, Dec. 8, 2014, 26(6):923-937.
Kosicki et al., Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements,: Nature Biotechnology, 2018, 1-8.
Lute et al., “Human CTLA4 knock-in mice unravel the quantitative link between minor tumor immunity and autoimmunity induced by anti-CTLA4 antibodies,” Blood. 106:3127-3133.
Lute et al., “Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies,” Blood, 2005, 106(9):3127-3133.
Maksimenko et al., (2013, Acta Naturae, vol. 5, No. 1, p. 33-46).
Munoz et al. “Constraints to progress in embryonic stem cells from domestic species,” Stem Cell Rev. and Rep., 2009, 5:6-9.
PCT International Preliminary Report on Patentability in International Appln. No. PCT/CN2017/099576, dated Mar. 5, 2019, 6 pages.
PCT International Search Report and Written Opinion in International Appln. No. PCT/CN2017/099576, dated Nov. 16, 2017, 12 pages.
Porteus et al., “Gene targeting using zinc finger nucleases,” Nature Biotechnology, 2005, 23(8):967-973.
Ristevski, “Making better transgenic models: Conditional, temporal, and spatial approaches,” Molecular Biotechnology, 2005, 29:153-163.
Rotte, “Combination of CTLA-4 and PD-1 blockers for treatment of cancer,” Journal of Experimental & Clinical Cancer Research, Dec. 2019, 38(1):1-12.
Sanmamed et al., “Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies,” Annals of Oncology, 2016, 27(7):1190-1198.
Sigmund, “Viewpoint: are studies in genetically altered mice out of control?” Arteroscler Thronn Vasc Biol, 2009, 20:1425-1429.
Stanietsky et al., “Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR,” Eur J Immunol., 2013, 43(8):2138-2150.
Tong et al., Generating gene knockout rats by homologous recombination in embryonic stem cells,: Nature Protocol, 827-844 (Year: 2011).
Topalian et al., “Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy,” Cancer Cell, 2015, 27(4):450-461.
Topalian et al., “Immune checkpoint blockade: a common denominator approach to cancer therapy,” Cancer Cell, 2015, 27:450-461.
Wheeler “Transgenic technology and applications in swine,” Theriogenology., 2001, 56:1345-1369.
Yin et al., “Delivery technologies for genome editing.” Nature Reviews Drug Discovery, 2017, 16(6):387-399.
Zhang et al., “T-cell immunoreceptor with Ig and ITIM domains precursor [Homo sapiens], GenBank Accession No. NP_776160.2,” NCBI GenBank, 2016, 4 pages.
Zhu et al., “Humanising the mouse genome piece by piece,” Nature communications, Apr. 23, 2019, 10(1):1-13.

Получить PDF